cas 202062-80-4|| where to buy 4-(1,3-dioxolan-2-yl)piperidine

Product Name:4-(1,3-dioxolan-2-yl)piperidine

IUPAC Name:4-(1,3-dioxolan-2-yl)piperidine

Packing Unit	Available Stock	Price($)
CM743777-1g	in stock	Ǌů
CM743777-5g	in stock	ůǤŉ
CM743777-10g	in stock	ǊŹƓ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 202062-80-4 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:202062-80-4; Molecular Formula:C8H15NO2; Melting Point:-; Smiles Code:C1COC(O1)C1CCNCC1; Density:

: Catalog Number:CM743777; Molecular Weight:157.21; Boiling Point:; MDL No:MFCD16547635; Storage:

: Piperidines; Piperidine is an azacycloalkane that is cyclohexane in which one of the carbons is replaced by a nitrogen. Although piperidine is a common organic compound, it is an immensely important class of compounds medicinally: the piperidine ring is the most common heterocyclic subunit among FDA approved drugs.; Piperidine,Piperidine Price; if you want to know the latest news about piperidine and piperidine price, please come to our website and get a quote for free.

: Dioxolanes; Dioxolane is a heterocyclic acetal with the formula (CH2)2O2CH2. It is related to tetrahydrofuran by exchanging an oxygen for the CH2 group. The isomer 1,2-dioxolane (in which the two oxygen centers are adjacent) is a peroxide. 1,3-Dioxolane is used as solvent and comonomer in polyacetal. The dioxolane-type and their hydrogenolysis can provide very valuable partially protected building blocks either for oligosaccharide syntheses or sugar transformations.

: NX-5948; Nurix announced the presentation of the first findings of clinical responses in the brain for NX-5948. NX-5948 is an investigational, orally bioavailable, brain penetrant, small molecule degrader of BTK. NX-5948 is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies.